Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 P901 | DOI: 10.1530/endoabs.110.P901

ECEESPE2025 Poster Presentations Pituitary, Neuroendocrinology and Puberty (162 abstracts)

Validation of arginine-stimulated copeptin cut-offs for diagnosing AVP deficiency (central diabetes insipidus)

Michelle Müller 1,2 , Cihan Atila 1,2 , Bettina Winzeler 1,2 , Irina Chifu 3 , Martin Fassnacht 3,4 , Julie Refardt 1,2,5 & Mirjam Christ-Crain 1,2


1University Hospital Basel, Department of Endocrinology, Diabetology and Metabolism, Basel, Switzerland; 2University Hospital Basel, Department of Clinical Research, Basel, Switzerland; 3University Hospital Wuerzburg, Division of Endocrinology and Diabetes, Department of Internal Medicine, Wuerzburg, Germany; 4University Hospital Wuerzburg, Central Laboratory, Wuerzburg, Germany; 5Erasmus Medical Centre, Rotterdam, Department of Internal Medicine, Section of Endocrinology, Rotterdam, Netherlands.


JOINT708

Background: Distinguishing arginine vasopressin (AVP) deficiency (central diabetes insipidus) from primary polydipsia is challenging. While hypertonic saline-stimulated copeptin testing provides the highest diagnostic accuracy, it is often restricted to specialised centres, requiring close monitoring and potentially causing patient discomfort. Initially, arginine-stimulated copeptin was proposed as a simpler alternative, but a head-to-head comparison study found it less precise than hypertonic saline stimulation. However, the same study identified two new high sensitivity and specificity cut-offs for arginine-stimulated copeptin, though these cut-offs have yet to be validated.

Methods: This is a secondary analysis of the initial prospective multicentre study, including adult patients with confirmed AVP deficiency or primary polydipsia. Participants underwent the arginine stimulation test, with plasma copeptin measured at baseline and 60- and 90 minutes after infusion. The primary objective was to revisit the original study to validate the proposed arginine-stimulated copeptin cut-offs of >5.2pmol/l (high sensitivity cutoff with >90% sensitivity) and ≤3pmol/l (high specificity cutoff with >90% specificity).

Findings: In total, 96 patients were included between May 2013 and June 2018: n=38 [40%] with AVP deficiency and n=58 [60%] with primary polydipsia. At 60 minutes after arginine infusion, a copeptin level ≤3.0 pmol/l showed a specificity of 95% (95% CI: 0.88-1.00) for AVP deficiency, while a copeptin level >5.2 pmol/l demonstrated a sensitivity of 97% (95% CI: 0.92-1.00) for primary polydipsia. The ≤3.0 pmol/l cut-off accurately identified 71% (n = 27/38) of patients with AVP deficiency, and the >5.2 pmol/l cut-off correctly identified 69% (n = 40/58) of patients with primary polydipsia.

Interpretation: This analysis validates two new copeptin cut-offs of the arginine stimulation test to distinguish AVP deficiency from primary polydipsia: >5.2 pmol/l for high sensitivity in diagnosing primary polydipsia and ≤3.0 pmol/l for high specificity in diagnosing AVP deficiency. These thresholds might offer a practical initial alternative to hypertonic saline testing.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches